SPIA
GERM

Steward Partners Investment Advisory’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Steward Partners Investment Advisory’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-160
Closed -$2.91K – 3895
2024
Q2 		$2.91K Hold
160
– – ﹤0.01% 3200
2024
Q1 		$2.94K Hold
160
– – ﹤0.01% 3202
2023
Q4 		$3.13K Hold
160
– – ﹤0.01% 3113
2023
Q3 		$2.86K Hold
160
– – ﹤0.01% 3004
2023
Q2 		$3.29K Hold
160
– – ﹤0.01% 2924
2023
Q1 		$3.27K Hold
160
– – ﹤0.01% 2916
2022
Q4 		$3.58K Hold
160
– – ﹤0.01% 2880
2022
Q3 		$3K Hold
160
– – ﹤0.01% 2984
2022
Q2 		$4K Hold
160
– – ﹤0.01% 2882
2022
Q1 		$4K Sell
160
-50
-24% -$1.41K ﹤0.01% 2994
2021
Q4 		$7K Sell
210
-1,400
-87% -$52.5K ﹤0.01% 2748
2021
Q3 		$66K Hold
1,610
– – ﹤0.01% 1746
2021
Q2 		$64K Hold
1,610
– – ﹤0.01% 2853
2021
Q1 		$57.1K Buy
1,610
+1,350
+519% +$50.6K ﹤0.01% 1917
2020
Q4 		$8K Hold
260
– – ﹤0.01% 2393
2020
Q3 		$7K Buy
+260
New +$7.64K ﹤0.01% 2284

Other funds holding GERM

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Steward Partners Investment Advisory's GERM Position: Q3 2024 in Review

Steward Partners Investment Advisory sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2024, closing a stake of 160 shares — an estimated $2.91K sold.

Steward Partners Investment Advisory first reported a position in GERM in Q3 2020 and held it in 16 quarters. The position peaked at $66K in Q3 2021. 1 fund tracked by Wall St. Rank holds GERM as of Q3 2024.

  • Steward Partners Investment Advisory reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2024 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 160 Amplify Treatments, Testing and Advancements ETF shares in Q3 2024, an estimated $2.91K.
  • Steward Partners Investment Advisory first reported a position in Amplify Treatments, Testing and Advancements ETF in Q3 2020 and held it in 16 quarters.
  • Steward Partners Investment Advisory's Amplify Treatments, Testing and Advancements ETF position peaked at $66K in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2024.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.